UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $35 and keeps a Buy rating on the shares. Lead program bexobrutideg, a bruton tyrosine kinase degrader, continues Phase 1b trial enrollment in chronic lymphocytic leukemia, and the firm expects Nurix to report updated durability data in mid-/2H25, the analyst tells investors in a research note. The firm sees “asymmetric” upside, with multiple data catalysts this year and the stock trading at a 52-week low.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Hold Rating for Nurix Therapeutics Amid Competitive Challenges and Strategic Uncertainties
- Nurix Therapeutics price target lowered to $32 from $35 at Oppenheimer
- Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo
- Nurix Therapeutics price target lowered to $35 from $36 at Stifel
- Nurix Therapeutics: Strong Financials and Strategic Collaborations Support ‘Buy’ Rating